National Comprehensive Cancer Network’s patient information team provides a patient and caregiver version of recently-updated, evidence-based expert consensus recommendations for vaccinating people with cancer against COVID-19.
A new analysis from the Geiger Gibson/RCHN Community Health Foundation Research Collaborative provides current information on the number of community health center staff members and patients who have received COVID-19 vaccines, using data from the latest published Health Resources and Services Administration’s Health Center COVID-19 Survey. The Geiger Gibson/RCHN Community Health Foundation Research Collaborative is based at the George Washington University Milken Institute School of Public Health (GW Milken Institute SPH).
A new Annals of Internal Medicine editorial co-authored by a University of Chicago Medicine health disparities researcher offers practical tips for clinicians to discuss the COVID-19 vaccine with patients of color who may be hesitant to get vaccinated.
The National Comprehensive Cancer Network put out new guidance for COVID-19 vaccinations in people with cancer, based on available evidence plus consensus from top hematology and oncology experts with particular expertise in infectious diseases, vaccine development and delivery, and medical ethics.
The Forum of International Respiratory Societies (FIRS), an organization comprised of the world’s leading international respiratory societies, including founding member the American Thoracic Society, calls for urgent access to affordable COVID-19 vaccines globally.
National efforts to develop a coronavirus disease 2019 (COVID-19) vaccine at “warp speed” will likely yield a safe and effective vaccine by early 2021. However, this important milestone is only the first step in an equally important challenge: getting a majority of the U.S. public vaccinated.
University Health Network (UHN) today gave the first COVID-19 vaccine in Canada. This landmark event signals a potential turning point in the pandemic and underlines the value of science and worldwide cooperation.
Associate Professor Tinglong Dai of the Johns Hopkins Carey Business School, an expert in health care industry operations management and business analytics, examines the daunting process of administering a COVID-19 vaccine globally.
MOSCOW (MIPT) — The race for producing and distributing COVID-19 vaccines is accelerating. Following the Pfizer-BioNTech announcement that came two weeks ago, yesterday U.K.-based drugmaker AstraZeneca claimed that its COVID-19 vaccine was 70% effective in trials and could reach 90% efficiency, making…
Competitors at all levels have been impacted by COVID-19. Team physicians, athletic trainers and physical therapists now face unique challenges caring for athletes. Top sports medicine experts will address key issues surrounding competitive and recreational athlete care during COVID-19 at the 2020 Advanced Team Physician Course, a collaborative effort between ACSM, AMSSM and AOSSM.
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.
Rush University Medical Center is recruiting participants for a nationwide trial of a COVID-19 vaccine developed by the University of Oxford in England and AstraZeneca, a multinational pharmaceutical company.
In this age of coronavirus, with vaccine experimentation moving at historic pace to the clinical trials phase, the ideal inoculation policy would emphasize age more than work-exposure risk, according to a study involving Washington University in St. Louis economists.
Gabriel Lockhart, MD, is a pulmonologist at National Jewish Health in Denver. Dr. Lockhart has volunteered for two stints in the ICU at Mount Sinai Health in New York City during the peak of their COVID cases. Currently, he is a…
A leading COVID-19 vaccine candidate developed at Beth Israel Deaconess Medical Center creates the groundwork for a newly launched COVID-19 vaccine clinical trial
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
While scientists around the world search for a coronavirus vaccine, an equivalent effort should be made to develop drugs that would mitigate the virus’s effects on patients, says Johns Hopkins Carey Business School Senior Lecturer Bonnie Robeson, who previously served as a principal investigator in drug discovery and development at the National Cancer Institute.
Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham, today announced progress towards the testing and development of an experimental vaccine called AAVCOVID, a novel gene-based vaccine candidate against SARS-CoV2, the virus that causes COVID-19. The AAVCOVID Vaccine Program is a unique, gene-based vaccine strategy that uses adeno-associated viral (AAV) vector, a clinically established gene transfer technology leveraging the properties of a harmless viral carrier.